

Joint Event

27th Euro-Global Summit on

Food and Beverages

19th International Conference on

Endocrinology and Metabolic Disorders

April 04-05, 2024

Madrid, Spain

Parth S. Shirode et al., Diabetes Case Rep 2024, Volume 09

Lenvatinib as a promising therapeutic choice for unresectable hurthle cell carcinoma: A case report

Parth S. Shirode, Anil D'cruz, Sataksi Chatterjee and Swayambhu Bhandarkar

Apollo Hospitals, Navi Mumbai, India

In this case report, we highlight the importance of Lenvatinib, a Tyrosine Kinase Inhibitor (TKI), as a management strategy for technically-unresectable Differentiated Thyroid Carcinoma (DTC). A 37-year-old gentleman presented with a locally advanced and widely metastasized case of large Hurthle cell carcinoma (HCC) encasing the left carotid sheath and the left recurrent laryngeal nerve. Fine needle aspiration cytology (FNAC) and very high (300,000 ng/ml) levels of serum thyroglobulin (Sr. TG) were suggestive of HCC. The patient received oral Lenvatinib 20 mg once daily as part of the treatment, and the response profile was assessed. The treatment protocol for thyroid cancers of any size that invade local structures is total thyroidectomy with extended resection. But surgical management is challenging if the tumor is locally advanced and invades major neck structures with an increased risk of recurrence. TKIs are used in the case of advanced disease, especially in unresectable, radio-iodine refractory, and metastatic status. Lenvatinib, a TKI, used as the first line of treatment, plays a key role in improving prognosis and survival rates among patients. The median progression-free survival (PFS) with Lenvatinib is 18.3 months. Whereas, in this patient, the treatment clinically translated into a good response in a high disease burden scenario and showed positive results with a PFS of 30 months and a reduction in the size of the tumor, along with an overall improvement of well-being.

Biography

Parth S. Shirode is a recent Medical Graduate (M.B.B.S.) from Terna Medical College, Hospital and Research Centre, Navi Mumbai, IND. He has had experience working as a Resident Medical Officer at Apollo Hospitals, Navi Mumbai, IND. There, he witnessed a rare case that he studied and successfully published under the guidance of Dr. Anil D'cruz of Head and Neck Surgery. Parth is a research enthusiast who is determined towards addressing the upcoming issues concerning the field of pediatrics through his articles. He aspires to be a dedicated pediatrician in the United States and is currently preparing for USMLE. He aims to contribute to the field of Medicine through his exceptional professional and clinical research skills in the years to come.

Received: February 05, 2024; **Accepted:** February 07, 2024; **Published:** April 04, 2024